Crossmark

Demographics, Disease Characteristics, and Time to Effective Treatment of Patients with Psoriasis in the Ghent PsoPlus Cohort of 2021

Published Online: 2024-10-04

Published Print: 2024-10

Authors

Meulewaeter, Evelyn

Eylenbosch, Anke

Verhaeghe, Evelien

Soenen, Rani

Lambert, Jo
License Information

Text and Data Mining valid from 2024-10-01

Version of Record valid from 2024-10-04
More Information

Article History

Received: 10 June 2024

Accepted: 13 September 2024

First Online: 4 October 2024

Declarations

:

: Jo Lambert has received grants scientific research grants (University of Ghent account) from Janssen, AbbVie and Pfizer; paid consultancies for scientific research (University of Ghent account) from AbbVie, Almirall, Argenx, BMS, Janssen Cilag, Pfizer, Leo Pharma, Novartis and UCB; and carried out clinical trials for Janssen-Cilag, Merck Serono, Amgen, Pfizer, AbbVie, Celgene, Regeneron and Novartis. All fees were paid to the University of Ghent. Evelyn Meulewaeter changed her affiliation during completion of the manuscript to Vitaz, Moerlandstraat 1, 9100 Sint-Niklaas. The other authors have no conflicts of interest to disclose.

: Approval of this study by the Ethical Committee of Ghent University Hospital (reference number BC-09420) was obtained. This study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments. All subjects provided written informed consent to participate in the study.

Document is current